CA3183663A1 - Engineered t cell receptors and methods of use - Google Patents

Engineered t cell receptors and methods of use

Info

Publication number
CA3183663A1
CA3183663A1 CA3183663A CA3183663A CA3183663A1 CA 3183663 A1 CA3183663 A1 CA 3183663A1 CA 3183663 A CA3183663 A CA 3183663A CA 3183663 A CA3183663 A CA 3183663A CA 3183663 A1 CA3183663 A1 CA 3183663A1
Authority
CA
Canada
Prior art keywords
tcr
seq
polypeptide
amino acid
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3183663A
Other languages
English (en)
French (fr)
Inventor
Cassian Yee
Ke Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3183663A1 publication Critical patent/CA3183663A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3183663A 2020-05-18 2021-05-17 Engineered t cell receptors and methods of use Pending CA3183663A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063026445P 2020-05-18 2020-05-18
US63/026,445 2020-05-18
PCT/US2021/032818 WO2021236548A1 (en) 2020-05-18 2021-05-17 Engineered t cell receptors and methods of use

Publications (1)

Publication Number Publication Date
CA3183663A1 true CA3183663A1 (en) 2021-11-25

Family

ID=78708026

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3183663A Pending CA3183663A1 (en) 2020-05-18 2021-05-17 Engineered t cell receptors and methods of use

Country Status (8)

Country Link
US (1) US20230190812A1 (https=)
EP (1) EP4153618A4 (https=)
JP (1) JP7785696B2 (https=)
CN (1) CN116322715A (https=)
AU (1) AU2021276264A1 (https=)
CA (1) CA3183663A1 (https=)
TW (1) TWI907427B (https=)
WO (1) WO2021236548A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3236237A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
CN114149978B (zh) * 2022-02-09 2022-04-26 深圳博雅感知药业有限公司 制备car-t细胞的方法
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
JP2026505826A (ja) 2023-02-03 2026-02-18 ゼルナ・イミュノセラピー・アーエス 抗ｍａｇｅ－ａ４ ｔ細胞受容体
CN120924527B (zh) * 2025-10-16 2026-02-06 内蒙古科为博生物科技有限公司 一种内切葡聚糖酶突变体eg06、其编码基因及其产品与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173480A3 (en) * 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
KR20140039318A (ko) * 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
CN106103711A (zh) * 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
US11047011B2 (en) * 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
PL3440105T3 (pl) * 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
AU2018318303A1 (en) * 2017-08-18 2020-04-09 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
US20210061914A1 (en) * 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
EP3731861A1 (en) * 2017-12-29 2020-11-04 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
EP3749753B1 (en) * 2018-02-09 2025-04-02 Immatics US, Inc. Methods for manufacturing t cells
DE102018108612A1 (de) * 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
EP3962939A4 (en) * 2019-05-03 2023-05-17 Gigamune, Inc. MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM

Also Published As

Publication number Publication date
EP4153618A1 (en) 2023-03-29
AU2021276264A1 (en) 2022-12-22
EP4153618A4 (en) 2024-06-26
JP7785696B2 (ja) 2025-12-15
TW202146438A (zh) 2021-12-16
JP2023528255A (ja) 2023-07-04
WO2021236548A1 (en) 2021-11-25
CN116322715A (zh) 2023-06-23
TWI907427B (zh) 2025-12-11
US20230190812A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
US20230190812A1 (en) Engineered t cell receptors and methods of use
US20240009241A1 (en) Engineered t cell receptors targeting egfr antigens and methods of use
EP4423116A1 (en) Methods and compositions for treating glioblastoma
US20230227526A1 (en) Engineered t cell receptors and methods of use
US20230143031A1 (en) Engineered t cell receptors and methods of use
US20260007698A1 (en) Peptides and engineered t cell receptors targeting vcy antigen and methods of use
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
US20240009240A1 (en) Engineered t cell receptors targeting egfr antigens and methods of use
CA3236237A1 (en) Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
HK40120545A (en) Engineered t cell receptors targeting egfr antigens and methods of use
WO2025096983A1 (en) Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
WO2025101705A1 (en) Peptides and engineered t cell receptors targeting a melanoma antigen preferentially expressed in tumors antigen and methods of use
WO2026019786A1 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
EP4716699A2 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250304

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250304

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250304

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250512

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250512

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250512

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250513

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250730

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250730

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250730

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250730

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250730

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260304

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260304